David Johnson

Johnson is currently CEO at VelosBio, a clinical-stage oncology company developing novel antibody-drug-conjugates and bispecific antibodies. Previously, he was CEO at Acerta Pharma. He has held roles with increasing responsibilities within commercial, pipeline development, medical affairs, and clinical development organizations at companies including Hoffman-La Roche, Immunex (acquired by Amgen), Millennium (acquired by Takeda), Favrille, Gloucester (acquired by Celgene), and Calistoga (acquired by Gilead).

  • March 2020

Added to: Zentalis Pharmaceuticals - New York, NY

Zentalis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing clinically differentiated, novel small molecule therapeutics that target fundamental biological pathways in cancer. They have an integrated discovery engine, broad therapeutic applicability and market potential with a strong pipeline across a broad range of oncology candidates, targeting areas of major unmet medical need.